Shaking Palsy of the Larynx – a Potential Biomarker for Multiple System Atrophy
Objective: To define a clinical biomarker that allows for early identification of Multiple System Atrophy. Background: In its early stages MSA can be difficult to…Freezer or non-freezer: what is in between?
Objective: This study aimed to characterize turning performance and clinical characteristics in people with definite, probable or no Freezing of Gait (FoG) in a cohort…Slow-Motion Analysis of Repetitive Tapping (SMART): a pilot study of a new measurement of bradykinesia
Objective: To assess repetitive tapping movements (RTM) using a slow motion camera and compare them with a clinician visual impression in people that have been…What connectivity tells us about neurodegeneration in Huntington disease? A fMRI study
Objective: Our study investigated the impact of Huntington disease (HD) on brain connectivity, through resting-state (RS) fMRI, among the most critical regions associated with physiopathology.…Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)
Objective: To determine the reliability and convergent validity of a novel digital monitoring platform offering objective, daily assessment of cognitive and motor symptom severity in…Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)
Objective: To explore the effect of laquinimod on brain volume in patients with Huntington Disease (HD). Background: Volume loss in caudate and other brain regions…Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
Objective: Evaluate if patients fulfill the recently developed “5-2-1” screening criteria for advanced Parkinson’s Disease (APD)[1] prior to treatment with levodopa-carbidopa intestinal gel (LCIG) and…High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy
Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease duration on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 217
- Next Page »